

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**信銘生命科技集團有限公司**

**Aceso Life Science Group Limited**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 00474)**

**DELAY IN PUBLICATION OF 2026 ANNUAL RESULTS;  
POSSIBLE DELAY IN DESPATCH OF 2026 ANNUAL REPORT;  
POSTPONEMENT OF BOARD MEETING;  
AND  
SUSPENSION OF TRADING**

This announcement is made by Aceso Life Science Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the provisions of inside information under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

**DELAY IN PUBLICATION OF 2026 ANNUAL RESULTS**

Pursuant to Rule 13.49(1) of the Listing Rules, the Company is required to publish an announcement for the annual results of the Group for the year ended 31 March 2026 (the “**2026 Annual Results**”) on a date not later than three months after the end of the financial year of the Company, i.e., on or before 30 June 2026. Under Rule 13.49(2) of the Listing Rules, the preliminary announcement in relation to the 2026 Annual Results shall be based on the Group’s consolidated financial statements for the financial year ended 31 March 2026 which shall have been agreed with the auditor of the Company (the “**Auditor**”).

The board of directors (the “**Director(s)**”) of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) that the Company will not be able to publish the 2026 Annual Results on or before 30 June 2026 in accordance with Rules 13.49(1) and (2) of the Listing Rules as additional time is required for the Company to collect and collate the requisite information, including, inter alia, the valuation of certain financial assets, associate and investment property, for the Auditor to complete the audit of the 2026 Annual Results.

Rule 13.49(3) of the Listing Rules provides that where a listed issuer is unable to issue its preliminary results in accordance with Rules 13.49(1) and (2) of the Listing Rules, it must announce its results based on the financial results that have yet to be agreed with the Auditor (so far as the information is available). The Board, after due and careful consideration, is of the view that it would not be appropriate for the Company to publish the unaudited management accounts of the Group for the financial year ended 31 March 2026 which are subject to audit at this stage, as such information may confuse or mislead the Shareholders and potential investors of the Company.

It is infeasible to estimate with certainty the approximate date of publication of the 2026 Annual Results and the Company will announce any updates on the same in due course. The Board and the management of the Company will continue to work closely with the Auditor so as to facilitate the completion of the remaining audit procedures and to publish the 2026 Annual Results. The Board wishes to emphasise that the operations of the Group remain normal. The Company will use its best endeavours to publish the 2026 Annual Results as soon as practicable and make further announcement(s) as and when appropriate, to inform the Shareholders regarding the date of publication of the 2026 Annual Results.

#### **POSSIBLE DELAY IN DESPATCH OF 2026 ANNUAL REPORT**

Pursuant to Rule 13.46(2) of the Listing Rules, the Company is required to despatch its annual report for the year ended 31 March 2026 (the “**2026 Annual Report**”) to the Shareholders no later than four months after the end of the financial year of the Company, i.e. on or before 31 July 2026. Due to the possible delay in the publication of the 2026 Annual Results, it is expected that there may be a possible delay in the despatch of the 2026 Annual Report.

The possible delay in despatch of the 2026 Annual Report, if materialised, will constitute a non-compliance with Rule 13.46(2) of the Listing Rules. The expected date of despatch of the 2026 Annual Report will be announced as and when appropriate.

#### **POSTPONEMENT OF BOARD MEETING**

As disclosed in the announcements of the Company dated 11 June 2026 and 24 June 2026, the meeting of the Board (the “**Board Meeting**”) was originally scheduled to be held on 30 June 2026 to consider and approve the 2026 Annual Results and its publication. Due to the aforesaid delay in the publication of the 2026 Annual Results, the Board Meeting will be postponed. The Company will make further announcement(s) in due course to inform the Shareholders of the latest information, if any, and the date of Board Meeting.

#### **SUSPENSION OF TRADING**

Trading in the shares of the Company on the Stock Exchange will be suspended with effect from 9:00 a.m. on Thursday, 2 July 2026 pending the publication of the 2026 Annual Results by the Company.

**The Company will make further announcement(s) in due course to inform the Shareholders and potential investors of the Company of any information update. The Shareholders and potential investors of the Company are reminded to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Aceso Life Science Group Limited**  
**Zhiliang Ou**  
*Executive Director*

Hong Kong, 30 June 2026

*As at the date of this announcement, the board of directors of the Company comprises two executive directors, namely Dr. Zhiliang Ou, J.P. (Australia) and Mr. Fok Chi Tak; one non-executive director, namely Ms. Jiang Yang; and three independent non-executive directors, namely Mr. Chan Ming Sun Jonathan, Mr. Lam Kwan Sing and Mr. Mak Yiu Tong.*